Clinical trials: Hyperplasia Prostatic
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hyperplasia
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal
This study is an open-label, randomized, fed, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tamsulosin HCl Tablet" and Astellas Phama Korea Inc.
- Trial name
- NCT03887871
- Testing
- Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Prostatic Neoplasms, Prostatic Hyperplasia
Prostate Mechanical Imager (PMI) Clinical Bridging Study
The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite…
- Trial name
- PMI (NCT00822952)
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Artann Laboratories
Benign Prostatic Hyperplasia
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- NCT01454349
- Testing
- PRX302
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia
Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH
The high level of unsatisfactory outcome observed in patients treated for LUTS associated with BPH with respect to the different existing therapeutic options strongly emphasizes the need for treatment optimisation in daily…
- Trial name
- UROEVAL (NCT03179670)
- Where
- France
- Volunteers
- 625 people
- Sponsor
- RECORDATI GROUP
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Prostatic Hyperplasia
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
- Trial name
- NCT00368979
- Testing
- Dutasteride
- Where
- 26 sites in Japan
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Hyperplasia Prostatic
Bioequivalence Study of Tansulosine 0,4 mg Capsule in Health Subjects -Fed State
The purpose of this study is to compare the bioavailability (rate and extent of absorption) of two tansulosine 0,4 mg capsule formulations.
- Trial name
- BET04cap (NCT01338623)
- Testing
- Tansulosine
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Biocinese
Prostatic Hyperplasia
Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin…
- Trial name
- NCT02058368
- Testing
- Dutasteride 0.5mg capsules, Tamsulosin 0.2mg tablets
- Where
- 46 sites in China, Japan and 2 more
- Volunteers
- 607 people
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device.
- Trial name
- Omega (NCT05757687)
- Testing
- Omega device
- Where
- 5 sites in Georgia
- Volunteers
- 11 people
- Sponsor
- ProArc Medical
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
MCS in the Treatment of Lower Urinary Tract Symptoms
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- Trial name
- MCS_LUTS (NCT01002417)
- Testing
- MCS-2 15 mg/day, MCS-2 30 mg/day
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Prostatic Hyperplasia
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
This will be an open-label, three-period, fixed-sequence study to evaluate the drug-drug interaction, pharmacokinetics and safety of dutasteride and tamsulosin when administered alone and in-combination in Chinese healthy male…
- Trial name
- NCT01957189
- Testing
- Dutasteride and Tamsulosin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bladder Outlet Obstruction
Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter"
Current gold standard of bladder outlet diagnosis is pressure flow study. This study is invasive time consuming and requires expensive and complex set-up.
- Trial name
- NCT01779349
- Testing
- Dynamic Urine Vibration "Holter"
- Where
- 2 sites in Israel
- Volunteers
- 45 people
- Sponsor
- P. Square Medical Ltd
Benign Prostatic Hyperplasia
The Zenflow Spring System Safety and Performance Study (ZEST CAN)
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT04309695
- Testing
- Zenflow Spring System
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia
Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System
To evaluate effect on cardiovascular system(blood pressure) when Thrupas® capsule is administered every day for 12 weeks in patients with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
- Trial name
- CV (NCT02029560)
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia, Adenoma, Prostatic
Rezum FIM Optimization Study
Evaluate the effect of the NxThera BPH Rezum System on prostate tissue in subjects suffering from LUTS symptoms secondary to benign prostatic hyperplasia (BPH).
- Conditions
- Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma, Prostatic Hyperplasia, Benign
- Trial name
- Rezum FIM (NCT02940392)
- Testing
- Rezum System
- Where
- Dominican Republic
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hypertrophy
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy…
- Trial name
- NCT00427219
- Testing
- Ozarelix
- Where
- 13 sites in United States
- Volunteers
- 74 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Benign Prostatic Hyperplasia
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
In patients with benign prostatic hyperplasia (BPH), combination therapy with an alpha-blocker (AB) and a 5 alpha-reductase inhibitor (5ARI) has been shown to reduce the progression of acute urinary retention (AUR) and the…
- Trial name
- NCT01435954
- Testing
- Early combination therapy, Delayed combination therapy
- Volunteers
- 13,551 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company